WuXi Biologics (Cayman)'s revenue for the
six
months ended in Jun. 2023 was €1,095 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €2,192 Mil.
WuXi Biologics (Cayman)'s Revenue per Share for the
six
months ended in Jun. 2023 was €0.25.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.50.
Warning Sign:
WuXi Biologics (Cayman) Inc revenue growth has slowed down over the past 12 months.
During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average Revenue per Share Growth Rate was 65.30% per year. The lowest was 42.10% per year. And the median was 53.35% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi Biologics (Cayman)'s Revenue
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman)'s Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Revenue distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Revenue falls into.
WuXi Biologics (Cayman) Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2,192 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
WuXi Biologics (Cayman) Revenue Related Terms
Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
WuXi Biologics (Cayman) (FRA:1FW2) Business Description
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:1FW2 has been successfully added to your 